title: Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition.
abstract: The use of adjuvant aromatase inhibitors is associated with an increased risk of osteoporosis and fractures. The oral bisphosphonate, risedronate--dosed as the US Food and Drug Administration approved for the treatment or prevention of postmenopausal osteoporosis--appears to mitigate bone loss associated with 2 years of adjuvant anastrozole in women with early-stage breast cancer.
authors.forename: Catherine
authors.initials: C
authors.lastname: Van Poznak
mesh_terms: D001141:Aromatase / Q000737:chemistry*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans
chemical_list: D047072:Aromatase Inhibitors; D004164:Diphosphonates; D001141:Aromatase